The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma A Multicenter Retrospective Study from Northwest China

doi:10.1097/MD.0000000000002222

CORC > 兰州大学 > 兰州大学 > 第二临床医学院 > 期刊论文

	The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma A Multicenter Retrospective Study from Northwest China
	Zheng, Y; Wang, FL; Wu, GJ; Zhang, LL; Wang, YM; Wang, ZP; Chen, P; Wang, Q; Lu, JY; Wang, YJ
刊名	MEDICINE
	2015-12
卷号	94 期号:49
ISSN号	0025-7974
DOI	10.1097/MD.0000000000002222
文献子类	Article
英文摘要	The aim of the study is to evaluate the relationship between the adverse events and efficacy of sorafenib in patients with metastatic renal cell carcinoma (mRCC), with a purpose to guide the judgment of efficacy in sorafenib treatment.Eighty-three mRCC patients who received sorafenib therapy at northwest China were studied retrospectively. Univariate and multivariate analyses were performed to correlate tumor response, progression-free survival (PFS), and overall survival (OS) with adverse event types and grades.Among 83 patients who underwent sorafenib therapy, 2 cases (2.4%) had completed response (CR), 14 cases (16.9%) had partial response (PR), 57 cases (68.7%) had stable disease (SD), and 10 cases (12.0%) developed progressive disease (PD). The median PFS and OS were 15.0 and 29.0 months, respectively. The most frequent grade 1 or 2 adverse events included hand-foot syndrome (68.7%), diarrhea (54.2%), and alopecia (51.8%). The most common grade 3 or 4 adverse events were hand-foot syndrome (6.0%), hypertension (4.8%), and diarrhea (3.6%). The frequency and severity of adverse events correlated with tumor response rate (both with P < 0.05). Multivariate analysis showed the independent predictors of better PFS included rash (OR 0.307, 95%CI 0.148-0.636, P=0.001) and diarrhea (OR 0.391, 95%CI 0.169-0.783, P=0.008). Elevated transaminase was the independent predictor of poor PFS (OR 2.606, 95%CI 1.299-5.532, P=0.012). For OS, rash (OR 0.473, 95%CI 0.253-0.886, P=0.019) and diarrhea (OR 0.321, 95%CI 0.171-0.605, P=0.000) correlated with better OS.Sorafenib-related adverse events are associated with efficacy in patients with mRCC from northwest China. Rash and diarrhea are independent protective factors of both PFS and OS, and elevated transaminase is an independent risk factor of PFS. A large prospective study is warranted.
学科主题	General & Internal Medicine
出版地	PHILADELPHIA
项目编号	Shaanxi Province technological pooling fund [2012KTCL03-03] ; Xijing Hospital subject booster plan translational medicine research [XJZT13Z05]
语种	英语
WOS记录号	WOS:000369541600042
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/179409]
专题	第二临床医学院_期刊论文
通讯作者	Yuan, JL (reprint author), Fourth Mil Med Univ, Xijing Hosp, Dept Urol, Xian 710032, Shaanxi, Peoples R China.
推荐引用方式 GB/T 7714	Zheng, Y,Wang, FL,Wu, GJ,et al. The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma A Multicenter Retrospective Study from Northwest China[J]. MEDICINE,2015,94(49).
APA	Zheng, Y.,Wang, FL.,Wu, GJ.,Zhang, LL.,Wang, YM.,...&Yuan, JL .(2015).The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma A Multicenter Retrospective Study from Northwest China.MEDICINE,94(49).
MLA	Zheng, Y,et al."The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma A Multicenter Retrospective Study from Northwest China".MEDICINE 94.49(2015).